Search results
16 kwi 2020 · ImmuneCyte Inc. is a global, clinical-stage biopharmaceutical company engaged in the research and development of innovative cell and gene therapeutics, including chimeric antigen receptor (CAR)-T cell, CAR-NK cell, and mononuclear cell therapies, for the treatment of cancer, vascular, orthopedic and aging-related diseases.
- ThermoGenesis Unveils Comprehensive Suite of Products and ... - ImmuneCyte
In response, ThermoGenesis, along with its joint venture...
- HealthBanks’ Subsidiary ImmuneCyte Acquires Boyalife’s Cellular Therapy ...
The combined companies will focus on expanding the...
- ThermoGenesis Unveils Comprehensive Suite of Products and ... - ImmuneCyte
3 wrz 2020 · In response, ThermoGenesis, along with its joint venture ImmuneCyte, is developing a comprehensive list of RT-PCR and antigen test products to complement its SARS-CoV-2 IgM/IgG Antibody Test Kit, which has already been granted Emergency Use Authorization (EUA).
A HealthBanks Biotech Company | ImmuneCyte Inc. is a global, clinical-stage biopharmaceutical company engaged in the research and development of innovative cell and gene therapeutics, including...
8 mar 2021 · The combined companies will focus on expanding the development of the next generation of cancer treatment therapies, including chimeric antigen receptor (CAR)-T cell therapy and CAR-NK cell therapy, as well as other cell-based therapies for rare genetic disorders.
ImmuneCyte is a multilingual, clinical-stage biopharmaceutical firm dedicated to the study and creation of alternative cell and gene medicines, such as CAR-NK, mononuclear, and T cells with chimeric antigen receptors, for the treatment of cancer, vascular, orthopaedic, and age-related illnesses.
2 wrz 2020 · In response, ThermoGenesis, along with its joint venture ImmuneCyte, is developing a comprehensive list of RT-PCR and antigen test products to complement its SARS-CoV-2 IgM/IgG Antibody Test Kit...
13 kwi 2020 · ImmuneCyte, which is a joint venture between ThermoGenesis Holdings Inc. and HealthBanks Biotech, acquired global intellectual property for four antibody drug candidates against SARS-CoV-2 — the virus that causes COVID-19 — and tools for screening and checking the efficacy of such antibodies.
